- JP-listed companies
- Income statement
(4893) Income statement
Market cap
¥6.4B
P/E ratio
Develops cancer immunotherapy treatments for solid tumors using proprietary PRIME technology that enhances immune cell activation and generates revenue through both in-house drug development and technology licensing.
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 1,558 | 521 | 97 | 101 | 626 | 317 | 8 | 5 |
| Revenue growth (%) | - | |||||||
| Operating margin (%) | - | - | - | |||||
| Operating income | - | - | - | -768 | -106 | -775 | -1,069 | -797 |
| Income before tax | 1,192 | 57 | -605 | -793 | -384 | -1,128 | -962 | -791 |
| Pretax margin (%) | 76.5 | 10.9 | -621.5 | -786.9 | -61.4 | -355.9 | -12,680 | -15,822.3 |
| Provision for income taxes | - | - | - | 2 | 2 | 2 | 2 | 2 |
| Effective tax rate (%) | - | - | - | |||||
| Net income | 872 | 55 | -637 | -795 | -387 | -1,130 | -964 | -794 |
| Earnings per share | 1,285.23 | 7.99 | -89.64 | -20.75 | -9.87 | -27.25 | -22.28 | -18.33 |
| Dividend per share | - | - | - | - | - | - | - | - |